RASAGILINE

Bivalirudin

Rasagiline is a strong irreversible monoamine oxidase (MAO)-B selective inhibitor which may additionally cause an increase in extracellular levels of dopamine within the striatum, further leading to decreased symptomatic motor deficits of Parkinson’s disease.

Rasagiline is used in the treatment of Idiopathic parkinsonism

Do not give Rasagiline to patients with the following conditions:

  • Severe liver impairment
  • Concomitant use with other MAOIs and pethidine within 14 days after discontinuation of therapy
  • Those using St John’s wort

Rasagiline may give rise to the following side effects:

  • Angina pectoris
  • Anorexia
  • Arthralgia
  • Arthritis
  • Cerebrovascular attack
  • Conjunctivitis
  • Depression
  • Dyspepsia
  • Flu-like syndrome
  • Headache
  • Heart attack
  • Leucopenia
  • Malaise
  • Melanoma
  • Neck pain
  • Rhinitis
  • Skin rashes
  • Urinary urgency
  • Vertigo

Precautions

Special precautions should be observed by people with the following conditions:

  • Mild to moderate liver impairment
  • Pregnancy
  • Lactation

 

Interactions

Rasagiline may interact with the following medicines:

  • Potent CYP1A2 inhibitors (example ciprofloxacin)
  • Entacapone
  • Other MAOIs and pethidine

Symptoms of Rasagiline overdose include the following:

  • Dysphoria
  • Hypomania
  • Hypertensive crisis and serotonin syndrome

 

Seek medical help immediately.

Available Brands:

  • Azilect

Related Articles

ULTRAVIST

UsesWarningsSide EffectsPrecautionsOverdose & BrandsUses Ultravist is used in the following conditions: Radiographic Imaging: Iopromide injection is utilized to enhance the [...]

ULTRAMOX

UsesWarningsSide EffectsPrecautionsOverdose & BrandsUses Ultramox is used in the following conditions: Respiratory Infections: Amoxicillin is often used to treat respiratory [...]

ULTRALIV

UsesWarningsSide EffectsPrecautionsOverdose & BrandsUses Ultraliv is used in the following conditions: Carnitine Orotate: Carnitine orotate is a combination of L-carnitine [...]